RayKnowChina Research Map
Shortlist0

RecruitingB-cell acute lymphoblastic leukaemiaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by Shenzhen University General Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShenzhen University General Hospital深圳大学总医院ShenzhenHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07584889, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. • Histologically or cytologically diagnosed with relapsed/refractory CD19-positive hematologic malignancy according to the 2022 World Health Organization (WHO) diagnostic criteria;

    Inclusion criterion 2

    • CD19 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;

    Inclusion criterion 6

  3. Class III or IV cardiac insufficiency according to the New York Heart Association (NYHA) functional classification, or left ventricular ejection fraction (LVEF) <50% by echocardiography;

    Inclusion criterion 12

  4. • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

    Inclusion criterion 3

  5. Complete blood count meeting any of the following criteria: white blood cell count (WBC) ≤1 × 10⁹/L, absolute neutrophil count (ANC) ≤0.5 × 10⁹/L, absolute lymphocyte count (ALC) ≤0.5 × 10⁹/L, or platelet count (PLT) ≤25 × 10⁹/L;

    Inclusion criterion 10

    Laboratory abnormalities including, but not limited to, serum total bilirubin ≥1.5 mg/dL; serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal; or serum creatinine ≥2.0 mg/dL;

    Inclusion criterion 11

  6. Pregnant or breastfeeding;

    Inclusion criterion 25

    Planning to become pregnant during the study; or

    Inclusion criterion 26

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07584889, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria

Subjects must meet all of the following criteria to be enrolled:

  • • Aged 18 to 75 years, male or female;
  • • Histologically or cytologically diagnosed with relapsed/refractory CD19-positive hematologic malignancy according to the 2022 World Health Organization (WHO) diagnostic criteria;
  • • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  • • Life expectancy of at least 3 months;
  • • No contraindications to peripheral blood leukapheresis;
  • • CD19 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;
  • • No severe cardiac, pulmonary, hepatic, or renal dysfunction;
  • • Able to understand and willing to provide written informed consent. Exclusion Criteria

Subjects who meet any of the following criteria should be excluded from enrollment:

  • History of allergy to any component of the cellular product;
  • Complete blood count meeting any of the following criteria: white blood cell count (WBC) ≤1 × 10⁹/L, absolute neutrophil count (ANC) ≤0.5 × 10⁹/L, absolute lymphocyte count (ALC) ≤0.5 × 10⁹/L, or platelet count (PLT) ≤25 × 10⁹/L;
  • Laboratory abnormalities including, but not limited to, serum total bilirubin ≥1.5 mg/dL; serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal; or serum creatinine ≥2.0 mg/dL;
  • Class III or IV cardiac insufficiency according to the New York Heart Association (NYHA) functional classification, or left ventricular ejection fraction (LVEF) <50% by echocardiography;
  • Abnormal pulmonary function, with oxygen saturation <92% on room air;
  • History of myocardial infarction, cardiac angioplasty or stent placement, unstable angina, or other clinically significant severe cardiac disease within 12 months prior to enrollment;
  • Grade 3 hypertension with poor blood pressure control despite medication;
  • History of traumatic brain injury, disturbance of consciousness, epilepsy, severe cerebral ischemia, or cerebral hemorrhagic disease;
  • Autoimmune disease, immunodeficiency, or other conditions requiring treatment with immunosuppressive agents;
  • Uncontrolled active infection;
  • Prior treatment with any CAR-T cell product or other genetically modified T-cell therapy;
  • Receipt of a live vaccine within 4 weeks prior to enrollment;
  • Positive test results for HIV, HBV, HCV, or TPPA/RPR, or HBV carrier status;
  • History of alcohol abuse, drug abuse, or psychiatric illness;
  • Participation in any other clinical study within 3 months prior to enrollment in this clinical study;
  • Female subjects who meet any of the following conditions:
  • Pregnant or breastfeeding;
  • Planning to become pregnant during the study; or
  • Of childbearing potential and unwilling or unable to use effective contraception;
  • Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07584889, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07584889, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07584889